Herta Steinkellner

Dr. Herta Steinkellner

orcid

Research Focus & Metrics

Academic Career Length

40Years (1987-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 March 2008 in Plant Biotechnology Journal
Verified
Journal Article
Open access
PDF file
RSRichard Strasser
Richard Strasser
JSJohannes Stadlmann
Johannes Stadlmann
MSMatthias Schähs
Matthias Schähs
GSGabriela Stiegler
Gabriela Stiegler
HQHeribert Quendler
Heribert Quendler
HSHerta Steinkellner
Herta Steinkellner
Summary: A common argument against using plants as a production system for therapeutic proteins is their inability to perform authentic human N‐glycosylation (i.e. the presence of β1,2‐xylosylation and core α1,3‐fucosylation). In this study, RNA interference (RNAi) technology was used to obtain a targeted down‐regulation of the endogenous β1,2‐xylosyltransferase (XylT) and α1,3‐fucosyltransferase (FucT) genes in Nicotiana benthamiana, a tobacco‐related plant species widely used for recombinant protein expression. Three glyco‐engineered lines with significantly reduced xylosylated and/or core α1,3‐fucosylated glycan structures were generated. The human anti HIV monoclonal antibody 2G12 was transiently expressed in these glycosylation mutants as well as in wild‐type plants. Four glycoforms of 2G12 differing in the presence/absence of xylose and core α1,3‐fucose residues in their N‐glycans were produced. Notably, 2G12 produced in XylT/FucT‐RNAi plants was found to contain an almost homogeneous N‐glycan species without detectable xylose and α1,3‐fucose residues. Plant‐derived glycoforms were indistinguishable from Chinese hamster ovary (CHO)‐derived 2G12 with respect to electrophoretic properties, and exhibited functional properties (i.e. antigen binding and HIV neutralization activity) at least equivalent to those of the CHO counterpart. The generated RNAi lines were stable, viable and did not show any obvious phenotype, thus providing a robust tool for the production of therapeutically relevant glycoproteins in plants with a humanized N‐glycan structure.

20 February 2004 in FEBS Letters
Verified
Journal Article
Closed access
RSRichard Strasser
Richard Strasser
FAFriedrich Altmann
Friedrich Altmann
LML. Mach
L. Mach
JGJ. Glössl
J. Glössl
HSHerta Steinkellner
Herta Steinkellner

1 May 1999 in Molecular Ecology
Verified
Journal Article
Closed access
PDF file
STStreiff
Streiff
DUDucousso
Ducousso
LELexer
Lexer
HSHerta Steinkellner
Herta Steinkellner
GLGloessl
Gloessl
KRKremer
Kremer

1 April 1997 in Plant Molecular Biology
Verified
Journal Article
Closed access
PDF file
HSHerta Steinkellner
Herta Steinkellner
SFS. Fluch
S. Fluch
ETE. Turetschek
E. Turetschek
CLC. Lexer
C. Lexer
RSR. Streiff
R. Streiff
JGJ. Glössl
J. Glössl

1 March 1998 in Molecular Ecology
Verified
Journal Article
Closed access
PDF file
RSRéjane Streiff
Réjane Streiff
TLThierry Labbe
Thierry Labbe
RBRoberto Bacilieri
Roberto Bacilieri
HSHerta Steinkellner
Herta Steinkellner
JGJoseph Glössl
Joseph Glössl
AKAntoine Kremer
Antoine Kremer

5 December 2011 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
LZLarry Zeitlin
Larry Zeitlin
JPJames Pettitt
James Pettitt
CSCorinne Scully
Corinne Scully
NBNatasha Bohorova
Natasha Bohorova
DKDo Kim
Do Kim
GOGene Garrard Olinger
Gene Garrard Olinger
No countermeasures currently exist for the prevention or treatment of the severe sequelae of Filovirus (such as Ebola virus; EBOV) infection. To overcome this limitation in our biodefense preparedness, we have designed monoclonal antibodies (mAbs) which could be used in humans as immunoprotectants for EBOV, starting with a murine mAb (13F6) that recognizes the heavily glycosylated mucin-like domain of the virion-attached glycoprotein (GP). Point mutations were introduced into the variable region of the murine mAb to remove predicted human T-cell epitopes, and the variable regions joined to human constant regions to generate a mAb (h-13F6) appropriate for development for human use. We have evaluated the efficacy of three variants of h-13F6 carrying different glycosylation patterns in a lethal mouse EBOV challenge model. The pattern of glycosylation of the various mAbs was found to correlate to level of protection, with aglycosylated h-13F6 providing the least potent efficacy (ED50= 33 μg). A version with typical heterogenous mammalian glycoforms (ED50= 11 μg) had similar potency to the original murine mAb. However, h-13F6 carrying complexN-glycosylation lacking core fucose exhibited superior potency (ED50= 3 μg). Binding studies using Fcγ receptors revealed enhanced binding of nonfucosylated h-13F6 to mouse and human FcγRIII. Together the results indicate the presence of FcN-glycans enhances the protective efficacy of h-13F6, and that mAbs manufactured with uniform glycosylation and a higher potency glycoform offer promise as biodefense therapeutics.